EMS Market Leader from Germany Standardizes on Masimo's Revolutionary Rainbow
SET Pulse CO-Oximetry Technology Platform
IRVINE, Calif. and KAUFERING, Germany, Aug. 20 /PRNewswire-FirstCall/ --
Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and
Measure-Through Motion and Low-Perfusion pulse oximetry, and GS
Elektromedizinische Gerate G. Stemple GmbH, a German developer and
manufacturer of innovative medical equipment for the Emergency Medical
Services (EMS), today jointly announced a worldwide technology licensing
agreement to integrate Masimo Rainbow SET Pulse CO-Oximetry into corpuls
patient monitoring modules. The agreement enables GS GmbH to expand the vital
signs and noninvasive measurement capabilities of its defibrillators and
patient monitoring systems to help EMS professionals detect and treat
life-threatening conditions earlier.
The breakthrough noninvasive blood constituent monitoring capabilities of
Masimo Rainbow SET Pulse CO-Oximetry allow for continuous monitoring of
hemoglobin, carbon monoxide, methemoglobin, PVI for fluid responsiveness,
perfusion index, and measure-through motion pulse oximetry. With Masimo
Rainbow SET, the ability to detect internal bleeding, carbon monoxide
poisoning, methemoglobinemia, fluid responsiveness, perfusion, saturation, and
pulse rate quickly, easily and continuously can help save lives and improve
patient outcomes.
According to Klaus Stemple, General Manager of GS GmbH, the key to
"developing better lifesaving support solutions and techniques is to stay
ahead of the mainstream. Our corpuls products are innovative leaders in the
defibrillator market and the integration of Masimo Rainbow SET Pulse
CO-Oximetry measurements is another consistent step in the design and
manufacture state-of-the-art defibrillator/monitoring-systems that spearhead
the industry in patient monitoring performance. The combination of corpuls and
Masimo Rainbow SET creates a unique defibrillator solution for EMS
professionals looking to leverage additional vital parameters to more
thoroughly assess a patient's physiological status and make better clinical
and treatment decisions."
The corpuls3--a unique 3-in-1 modular defibrillator system combining three
components including: a compact patient box, a large monitoring unit, and a
defibrillator/pacer unit -- will be one of the first products to feature
Masimo Rainbow SET Pulse CO-Oximetry capabilities. The Masimo Rainbow SET
measurement option will be available in mid-2010.
Masimo Founder and CEO, Joe E. Kiani, stated, "GS GmbH was one of the
first European equipment manufacturers to license Masimo SET pulse oximetry
technology over 10 years ago. Today, they are still a market leader in
providing innovative EMS solutions throughout Europe and, with this technology
license agreement, will further expand the availability of Masimo Rainbow SET
Pulse CO-Oximetry to the benefit of patients and EMS professionals alike."
About GS GmbH
GS Elektromedizinische Gerate G. Stemple GmbH is a German company and
internationally-operated business specializing in the development and
manufacture of innovative high-end medical devices for emergency medical
services and intensive care for over 25 years. The corpuls defibrillators and
patient monitoring systems are robust, reliable and durable devices designed
for use in the first aid treatment of people suffering from sudden cardiac
arrest. Additional information about corpuls and its products may be found at
www.corpuls.com.
About Masimo
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care--helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low-Perfusion pulse
oximetry, known as Masimo SET , which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry(TM), a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO ),
methemoglobin (SpMet ), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks related to our
assumptions regarding the timing and commercial availability of corpuls3
featuring Masimo Rainbow SET Pulse CO-Oximetry technology, risks related to
our belief that Masimo Rainbow SET will provide sufficient sensitivity and
specificity to detect physiological abnormalities in real-time, enabling EMS
professionals to detect and identify potentially life-threatening conditions
earlier and make better clinical and treatment decisions for their patients,
as well as other factors discussed in the "Risk Factors" section of our most
recent reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov. Although
we believe that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove correct.
All forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any obligation to
update, amend or clarify these forward-looking statements or the "Risk
Factors" contained in our most recent reports filed with the SEC, whether as a
result of new information, future events or otherwise, except as may be
required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8,
Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered
trademarks of Masimo Corporation. Corpuls and Corpuls3 are trademarks or
registered trademarks of GS Elektromedizinische Gerate G. Stemple GmbH.
Media Contacts:
Dana Banks
Masimo Corporation
+1 (949) 297-7348
SOURCE Masimo Corporation
Web Site:
http://www.masimo.com
http://www.corpuls.com